van Straalen K R, Schneider-Burrus S, Prens E P
Department of Dermatology, Erasmus University Medical Centre, Rotterdam, the Netherlands.
Department of Dermatology, University Hospital Charité, Berlin, Germany.
Br J Dermatol. 2020 Dec;183(6):e178-e187. doi: 10.1111/bjd.16768. Epub 2018 Jul 7.
This scholarly review on the current and future treatment of hidradenitis suppurativa (HS) focuses on medical and surgical treatment options, while novel pipeline drugs are also discussed. Treatment goals are to limit the incidence and duration of flares, reducing inflammation and suppuration, achieving local cure after surgery and, most importantly, to improve the quality of life of patients with HS. The type of medication and/or surgery should be chosen based on the stage of the disease and the degree of inflammation. However, the lack of a simple scoring system and the lack of clear surgical outcome definitions hamper the interpretation of treatment efficacy and the comparison between different treatment strategies. The therapeutic pipeline for HS is gradually expanding, and will probably lead to a broader panel of more effective therapeutic options.
这篇关于化脓性汗腺炎（HS）当前及未来治疗的学术综述聚焦于药物和手术治疗方案，同时也讨论了处于研发阶段的新型药物。治疗目标是限制发作的发生率和持续时间，减轻炎症和化脓，术后实现局部治愈，最重要的是改善HS患者的生活质量。应根据疾病阶段和炎症程度选择药物类型和/或手术方式。然而，缺乏简单的评分系统以及明确的手术结果定义阻碍了对治疗效果的解读以及不同治疗策略之间的比较。HS的治疗渠道正在逐步拓展，可能会带来更多更有效的治疗选择。
